Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, PM Capital Global Companies Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities. Portfolio overweighted healthcare for offensive/defensive characteristics while taking advantage of small-cap discount to large caps."
The manager delivered strong Q3 2025 performance of +18% to +25% across portfolios, outperforming Russell 2000 Growth (+12%) and Russell 2500 Growth (+7%). The strategy focuses on small and mid-cap companies trading at attractive 16x earnings versus elevated large-cap valuations. Portfolio positioning has shifted toward healthcare overweight, viewed as both offensive through new products addressing large markets and defensive through non-discretionary characteristics. Key contributors included MDxHealth (prostate cancer diagnostics), Xeris Pharmaceuticals (Cushing's Syndrome treatment), and Zeta Global (marketing technology). The manager sees Federal Reserve rate cuts as a tailwind for small companies while acknowledging elevated magnificent-7 valuations and AI investment risks reminiscent of dot-com era practices. Despite macroeconomic and political uncertainty, the outlook remains optimistic based on company-specific fundamentals. The strategy emphasizes active stock selection over passive indexing, continuously screening for companies with new products, large market opportunities, and strong revenue growth with healthy margins.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Manager provides detailed analysis of 4 specific holdings with clear investment theses, position sizing context (small position for ELUT), and explicit actions taken (sold ELUT, continue holding XERS despite doubling). Healthcare overweight represents clear positioning conviction, though portfolio appears diversified beyond these named holdings.
Growth Outlook
Manager expresses optimism about company fundamentals and rate cut tailwinds for small caps, but acknowledges elevated valuations in large caps and compares AI investments to dot-com era risks. Constructive but balanced view.
Risk Appetite
Portfolio is positioned with healthcare overweight for defensive characteristics while taking some gains and offsetting with losses. Selective positioning rather than aggressive risk-on deployment.
Capital Deployment
Manager took some gains during the quarter and offset with losses for tax management, suggesting modest harvesting activity. Sold ELUT position entirely. No evidence of new cash deployment or significant position building.
Forward Guidance
Manager plans to continue screening for new ideas and re-evaluating portfolios while monitoring macro events. Balanced approach between opportunity seeking and cautious monitoring.
Language Signal
Language includes positive terms like 'tremendous investment opportunities' and 'optimistic' but also risk language around 'uncertainty,' 'elevated valuations,' and AI investment concerns. Slightly more cautious than bullish overall.
Perceived Risk
Manager identifies specific risks including elevated magnificent-7 valuations, macroeconomic and political uncertainty, and AI investment risks compared to dot-com era. Risks are named and discussed but not characterized as extreme or systemic threats.
Opportunity Density
Manager explicitly states 'we continue to see tremendous investment opportunities in the market' and emphasizes continuous screening for new ideas. Believes current environment provides opportunities for active stock selection over passive investing.
Time Horizon
Manager discusses multi-year revenue targets (XERS 2030 model of $750M revenue) and focuses on fundamental company performance regardless of economic backdrop. Emphasis on company-specific drivers suggests 2-3 year investment horizon rather than near-term catalyst dependency.
